
Principal investigator
Garry Duffy
Head of Department · Principal Investigator
Translational medicine · Medical devices · Chronic wound technologies · Infusion technologies
About
Research profile
Professor Garry Duffy is Head of Anatomy and Regenerative Medicine. His work spans translational medicine, technology transfer, medical-device development and commercialisation, including chronic-wound sensing and infusion technologies.
Expertise
Research interests
Lab members
Garry’s research team
No lab members are currently listed.
Current work
Research projects
Hydrogels
Injectable, printable and stimuli-responsive hydrogels for controlled delivery, tissue support and next-generation biomedical devices.
6 associated researchers
Explore research areaCardiovascular regeneration
Vascular grafts, heart-valve scaffolds, computational models, biosensors and device-based treatments for cardiovascular disease.
5 associated researchers
Explore research areaSkin and wound healing
Hydrogels and multilayered biomaterials that promote angiogenesis, control inflammation and infection, and support chronic-wound repair.
3 associated researchers
Explore research areaAdvanced disease models
Three-dimensional models of cancer, bone infection, osteoporosis, lung disease and other tissue microenvironments for discovery and screening.
7 associated researchers
Explore research areaMedical devices and implants
Microneedles, cardiovascular and neural implants, biosensors and minimally invasive devices for therapeutic delivery, monitoring and tissue repair.
5 associated researchers
Explore research areaSelected outputs
Highlighted publications
Dual scaffold delivery of miR-210 mimic and miR-16 inhibitor enhances angiogenesis and osteogenesis to accelerate bone healing.
Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction.
Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities.
Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity.
Rapid bone repair with the recruitment of CD206(+)M2-like macrophages using non-viral scaffold-mediated miR-133a inhibition of host cells.
Industry & translation
Turning research into impact.
TERG works with academic, clinical and industry partners to move biomaterials, devices and regenerative technologies towards patient benefit.
Industry, spin-outs and collaborationContact
Start a conversation.
For research, collaboration and supervision enquiries, email garryduffy@rcsi.com.
Lab contact details